Nabriva Therapeutics AG (Nasdaq: NBRV) to Ring The Nasdaq Stock Market Closing Bell
May 31 2016 - 10:00AM
What:Nabriva Therapeutics AG (Nasdaq:NBRV), a
clinical stage biopharmaceutical company engaged in the research
and development of novel anti-infective agents to treat serious
infections, with a focus on the pleuromutilin class of antibiotics,
will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Dr. Colin Broom, Chief
Executive Officer, will ring the Closing Bell.
Where:Nasdaq MarketSite – 4 Times Square – 43rd
& Broadway – Broadcast Studio
When:Wednesday, June 1, 2016 – 3:45 p.m. to
4:00 p.m. ET
Nabriva Therapeutics AG Media Contact:Will
SargentNabriva Therapeutics AGWilliam.Sargent@nabriva.com
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as
exclusive content, photo postings, status updates and video of bell
ceremonies, please visit our Facebook
page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our
YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our
Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Closing
Bell will be available at: https://new.livestream.com/nasdaq/live
or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Close, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market close of your choice.
About Nabriva Therapeutics AGNabriva
Therapeutics is a clinical stage biopharmaceutical company engaged
in the research and development of novel anti-infective agents to
treat serious bacterial infections, with a focus on the
pleuromutilin class of antibiotics. Nabriva's medicinal chemistry
expertise has enabled targeted discovery of novel pleuromutilins,
including both intravenous and oral formulations of its lead
product candidate. Nabriva's lead pleuromutilin product candidate,
lefamulin, is being developed to be the first systemically
available pleuromutilin for human use and is the first new class of
antibiotic to reach late stage clinical development for CABP in
over a decade. Nabriva believes lefamulin is well positioned for
use as a first-line empiric monotherapy for the treatment of
moderate to severe CABP due to its novel mechanism of action,
targeted spectrum of activity, resistance profile, achievement of
substantial drug concentration in lung tissue and fluid, oral and
IV formulations and favorable tolerability profile. Nabriva also
intends to further pursue the development of lefamulin for
additional indications, including the treatment of acute bacterial
skin and skin structure infections, and is developing a formulation
of lefamulin appropriate for pediatric use.
Nabriva owns exclusive, worldwide rights to lefamulin, which is
protected by composition of matter patents issued in the United
States, Europe and Japan.
About NasdaqNasdaq (Nasdaq:NDAQ) is a leading
provider of trading, clearing, exchange technology, listing,
information and public company services across six continents.
Through its diverse portfolio of solutions, Nasdaq enables
customers to plan, optimize and execute their business vision with
confidence, using proven technologies that provide transparency and
insight for navigating today's global capital markets. As the
creator of the world's first electronic stock market, its
technology powers more than 70 marketplaces in 50 countries, and 1
in 10 of the world's securities transactions. Nasdaq is home to
more than 3,700 listed companies with a market value of
approximately $9.3 trillion and nearly 17,000 corporate clients. To
learn more, visit: nasdaq.com/ambition or business.nasdaq.com.
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Apr 2023 to Apr 2024